Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2500502 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Multifaceted Role of Growth Differentiation Factor 15 (GDF15): A Narrative Review from Cancer Cachexia to Target Therapy.
Biomedicines
August 2025
Department of Internal Medicine and Medical Therapy, University of Pavia, 27100 Pavia, Italy.
Growth Differentiation Factor 15 (GDF15) has emerged as a key biomarker and therapeutic target in oncology, with roles extending beyond cancer cachexia. Elevated GDF15 levels correlate with poor prognosis across several solid tumors, including colorectal, gastric, pancreatic, breast, lung, prostate, and head and neck cancers. GDF15 modulates tumor progression through PI3K/AKT, MAPK/ERK, and SMAD2/3 signaling, thereby promoting epithelial-to-mesenchymal transition, metastasis, immune evasion, and chemoresistance via Nrf2 stabilization and oxidative stress regulation.
View Article and Find Full Text PDFSarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues.
J Cachexia Sarcopenia Muscle
June 2025
Berlin Institute of Health-Center for Regenerative Therapies (BCRT), Charité- Universitätsmedizin Berlin, Berlin, Germany.
In December 2024, the Society on Cachexia and Wasting Disorders (SCWD) hosted a Regulatory and Trial Update Workshop in Washington, D.C., bringing together experts from academia, industry, and the US Food and Drug Administration (FDA).
View Article and Find Full Text PDFOncology: What You May Have Missed in 2024.
Ann Intern Med
May 2025
Penn Medicine, Ann B. Barshinger Cancer Institute, Lancaster General Health, Lancaster, Pennsylvania (E.D.).
Over the past 5 decades, substantial advances in oncology have reshaped cancer care, reflecting the dynamic role of internal medicine physicians in patients' journey from screening to diagnosis, treatment, and surveillance. This review highlights 10 landmark studies from 2024 that address emerging therapies and evolving clinical standards. Immunotherapy remains a central focus, with checkpoint inhibitors redefining the management of solid tumors and showing expanded applications across disease sites and earlier stages of disease.
View Article and Find Full Text PDFNew trends in supportive care of head and neck cancers.
Curr Opin Oncol
May 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele.
Purpose Of Review: Supportive care plays a vital role in the management of head and neck cancer (HNC) patients, as the disease often affects a frail and older population that is treated with multiple strategies and is associated with severe symptoms. We will focus on mucositis, dermatitis, dysphagia, pain, cachexia, and infections, as they are among the most common and challenging symptoms encountered.
Recent Findings: Efforts have focused on multiomics approaches to decipher the complex biological pathways that drive symptom onset and treatment-related toxicities, with the aim of developing novel therapeutic strategies.
Ponsegromab for the Treatment of Cancer Cachexia. Reply.
N Engl J Med
March 2025
Pfizer, Cambridge, MA.